On July 3, Pentixapharm announced that it entered into an agreement to acquire certain discovery assets from Glycotope, a Berlin, Germany-based biotechnology company. The assets are aimed at various oncology targets and could be turned into radiopharmaceuticals.
Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It develops PentixaFor and PentixaTher, two small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in hematological and solid cancers, as well as cardiovascular and endocrine diseases.
This acquisition is aimed at doubling Pentixapharm’s pipeline of preclinical cancer antibodies. The financial terms of the acquisition were not disclosed.
“We look forward to maximizing the synergy of Pentixapharm’s know-how and Glycotope’s target discovery for the benefit of patients in both diagnostics and therapeutic applications,” said Pentixapharm’s CEO Hakim Bouterfa.
According to data captured in the LevinPro HC database, this transaction marks the 82nd Biotechnology acquisition of 2024. In the first half of 2023, there were 84 Biotechnology transactions reported.
